Haemonetics (NYSE:HAE) Stock Rating Reaffirmed by Barrington Research

Haemonetics (NYSE:HAE)‘s stock had its “outperform” rating reaffirmed by equities researchers at Barrington Research in a report issued on Friday, Benzinga reports. They currently have a $105.00 price target on the medical instruments supplier’s stock. Barrington Research’s price target points to a potential upside of 23.21% from the company’s previous close. Barrington Research also issued estimates for Haemonetics’ FY2026 earnings at $4.80 EPS and FY2027 earnings at $5.52 EPS.

HAE has been the subject of several other research reports. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd.

Haemonetics Stock Down 1.5 %

HAE stock opened at $85.22 on Friday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 2.04 and a beta of 0.36. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $95.26. The stock has a fifty day moving average of $78.23 and a 200-day moving average of $82.87.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. The company had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.85 EPS. As a group, equities research analysts predict that Haemonetics will post 3.95 earnings per share for the current year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Advisor Solutions LLC raised its holdings in shares of Haemonetics by 2.1% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock valued at $1,562,000 after acquiring an additional 374 shares in the last quarter. Miller Howard Investments Inc. NY purchased a new stake in shares of Haemonetics in the 1st quarter valued at about $372,000. Los Angeles Capital Management LLC raised its holdings in shares of Haemonetics by 5.0% in the 1st quarter. Los Angeles Capital Management LLC now owns 26,915 shares of the medical instruments supplier’s stock valued at $2,297,000 after acquiring an additional 1,277 shares in the last quarter. Kapitalo Investimentos Ltda raised its holdings in shares of Haemonetics by 80.4% in the 4th quarter. Kapitalo Investimentos Ltda now owns 3,636 shares of the medical instruments supplier’s stock valued at $311,000 after acquiring an additional 1,621 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after acquiring an additional 25,451 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.